# About Booking Peptides — An Independent Metabolic-Research Desk

> About Booking Peptides: an independent literature digest covering four metabolic research peptides. Editorial method, what this site is, and what it is not.

An independent, citation-anchored digest of the metabolic-peptide literature. Not a vendor. Not a clinic. Not medical advice.

## What Booking Peptides is

Booking Peptides is an independent editorial desk covering published research on four peptides studied for weight management and metabolic regulation: semaglutide, tirzepatide, retatrutide, and tesamorelin.

Despite the brand name, this site has nothing to do with appointments, clinic services, or purchasing. The name reflects a navigation frame — think of it as *booking a reading slot* in the literature, not booking a procedure. The site exists to do one thing: give a reader an accurate, plain-English account of what each compound was studied for, in which species, in which populations, and how far that evidence actually reaches.

The organizing idea is the metabolic theme. Three of the four compounds are incretin-class agents approaching weight management through gut-hormone signaling. The fourth, tesamorelin, approaches visceral fat through the GH/IGF-1 axis. Reading them together gives a fuller picture of how the metabolic-peptide field is structured — and where the gaps still are.

## Editorial method

Sources are peer-reviewed clinical trials, systematic reviews, meta-analyses, and authoritative drug-safety references (NIH LiverTox, FDA-reviewed StatPearls). Each compound page draws on a curated references set verified at publication and listed in the [references index](/references). Citations appear inline as bracketed numbers so readers can check every claim at source.

Where evidence is confined to specific populations (as with tesamorelin's HIV-lipodystrophy data), or where a compound is investigational (as with retatrutide), this desk says so clearly — it does not extrapolate beyond what the studies support. Where community reports add texture on reported effects and tolerability, they are labeled explicitly as anecdotal and unverified.

This desk does not cite secondary sources that do not in turn cite primary literature. No human dose appears anywhere on the site. No compound page recommends, prescribes, or implies a course of action.

The references list is shared across all pages. Readers should use DOIs and PMIDs to access source material directly — secondary sources, including this one, should be checked against the primary record.

## What this desk is not

To be direct:

- **Not a vendor or marketplace.** No products, no sourcing information, no pricing, no links to supply channels.
- **Not a clinic or telehealth service.** No appointments, no prescription consultation, no clinical guidance.
- **Not medical advice.** Nothing on this site constitutes a recommendation for any individual. If you have questions about a specific compound for a health condition, a licensed clinician is the appropriate resource.
- **Not affiliated with any pharmaceutical manufacturer.** Coverage is independent; no compound is promoted over another.
- **Not a current-events news feed.** The evidence base is from peer-reviewed literature; post-market and post-approval changes not yet in the cited corpus are not automatically reflected.

This is a reading desk. It tells you what the studies found. What to do with that information is not its business.

---

A literature digest — what the studies found, in the species studied, stated plainly and stopped.